Patient characteristics for the study cohort
| Characteristics . | Number . | Percentage (%) . |
|---|---|---|
| Women/men | 4/10 | 29/71 |
| Median age (range), y | 72 (38-81) | |
| Histological diagnosis | ||
| DLBCL | 9 | 64 |
| HGBL | 2 | 14 |
| PMBCL | 2 | 14 |
| FL, grade 3∗ | 1 | 7 |
| COO | ||
| GCB | 2 | 14 |
| Non-GCB | 6 | 43 |
| NR/UD | 6 | 43 |
| Extranodal involvement | ||
| 0-1 | 9 | 64 |
| ≥2 | 5 | 36 |
| IPI ≥4 | 6 | 43 |
| Ann Arbor stage III-IV | 11 | 79 |
| ECOG PS ≥2 | 4 | 29 |
| Elevated LDH | 9 | 64 |
| B-symptoms | 9 | 64 |
| First-line treatment | ||
| R-CHOP | 10 | 71 |
| R-CHOP–like regimens | 4 | 29 |
| Baseline PET-CT metrics | ||
| Median TMTV, cm3 | 450.5 | |
| Median SUVmax | 27.02 | |
| PET-CT response on first-line therapy | ||
| Interim | ||
| CMR | 8 | 57 |
| PMR | 4 | 29 |
| SD | 1 | 7 |
| PD | 1 | 7 |
| EOT (those completing first-line therapy) | ||
| CMR | 9 | 69 |
| PMR | 2 | 15 |
| PD | 2 | 15 |
| Status at study termination | ||
| Alive | 11 | 79 |
| Observation in CR | 10 | 71 |
| Relapse treatment ongoing | 1 | 7 |
| Death from progression | 3 | 21 |
| Characteristics . | Number . | Percentage (%) . |
|---|---|---|
| Women/men | 4/10 | 29/71 |
| Median age (range), y | 72 (38-81) | |
| Histological diagnosis | ||
| DLBCL | 9 | 64 |
| HGBL | 2 | 14 |
| PMBCL | 2 | 14 |
| FL, grade 3∗ | 1 | 7 |
| COO | ||
| GCB | 2 | 14 |
| Non-GCB | 6 | 43 |
| NR/UD | 6 | 43 |
| Extranodal involvement | ||
| 0-1 | 9 | 64 |
| ≥2 | 5 | 36 |
| IPI ≥4 | 6 | 43 |
| Ann Arbor stage III-IV | 11 | 79 |
| ECOG PS ≥2 | 4 | 29 |
| Elevated LDH | 9 | 64 |
| B-symptoms | 9 | 64 |
| First-line treatment | ||
| R-CHOP | 10 | 71 |
| R-CHOP–like regimens | 4 | 29 |
| Baseline PET-CT metrics | ||
| Median TMTV, cm3 | 450.5 | |
| Median SUVmax | 27.02 | |
| PET-CT response on first-line therapy | ||
| Interim | ||
| CMR | 8 | 57 |
| PMR | 4 | 29 |
| SD | 1 | 7 |
| PD | 1 | 7 |
| EOT (those completing first-line therapy) | ||
| CMR | 9 | 69 |
| PMR | 2 | 15 |
| PD | 2 | 15 |
| Status at study termination | ||
| Alive | 11 | 79 |
| Observation in CR | 10 | 71 |
| Relapse treatment ongoing | 1 | 7 |
| Death from progression | 3 | 21 |
COO, cell of origin; CR, complete remission; ECOG, Eastern Cooperative Oncology Group; FL, follicular lymphoma; GCB, germinal-center B cell; LDH, lactate dehydrogenase; NR, not reported; PD, progressive disease; PS, performance status; SD, stable disease; UD, undetermined.
This patient later transformed to DLBCL.